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ABSTRACT
Several virulence factors contribute to the pathogenesis of Proteus mirabilis. This study determined the inhibitory effects of
allicin on urease, hemolysin and biofilm of P. mirabilis ATCC 12453 and its antimicrobial activity against 20 clinical isolates
of P. mirabilis. Allicin did not inhibit hemolysin, whereas it did inhibit relative urease activity in both pre-lysed
(half-maximum inhibitory concentration, IC50 = 4.15 μg) and intact cells (IC50 = 21 μg) in a concentration-dependent
manner. Allicin at sub-minimum inhibitory concentrations (2–32 μg mL−1) showed no significant effects on the growth of
the bacteria (P > 0.05), but it reduced biofilm development in a concentration-dependent manner (P < 0.001). A higher
concentration of allicin was needed to inhibit the established biofilms. Using the microdilution technique, the MIC90 and
MBC90 values of allicin against P. mirabilis isolates were determined to be 128 and 512 μg mL−1, respectively. The results
suggest that allicin could have clinical applications in controlling P. mirabilis infections.
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INTRODUCTION
Proteus mirabilis, a member of the Enterobacteriaceae family, is
one of the leading causes of urinary tract infections (UTIs) in pa-
tients with indwelling catheters or structural abnormalities in
the urinary tract (Coker et al. 2000). ProteusmirabilisUTIs aremost
commonly associated with urinary tract obstruction, blockage
of urinary catheters, bladder and kidney stone formation, and
bacteriuria. Intrinsically, P. mirabilisUTIs are often persistent and
difficult to treat (Rozalski, Sidorczyk and Kotelko 1997). Further-
more, the development of extended spectrum beta-lactamase
producing and multiple drug resistant strains of P. mirabilis
(Mokracka, Gruszczynska and Kaznowski 2012; Kurihara et al.
2013) have made treating P. mirabilis infections more diffi-
cult. Therefore, finding antibiotics with new modes of action
and alternatives to commonly used antimicrobial therapies for
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treating P. mirabilis infections is urgently needed. Neutralizing
or suppressing the expression of the pathogen’s virulence fac-
tors is desired to overcome infections (Fernebro 2011); it attenu-
ates the pathogenicity of the bacterium and makes it easier for
the host innate immune system to clear the infection (Fernebro
2011). Proteus mirabilis produces several potential virulence fac-
tors responsible for the pathogenicity of the organism, includ-
ing urease and hemolysin (Rozalski, Sidorczyk and Kotelko 1997;
Coker et al. 2000). Urease is produced by virtually all clinical
strains of the bacterium (Rozalski, Sidorczyk and Kotelko 1997;
Stankowska, Kwinkowski and Kaca 2008) and catalyzes the hy-
drolysis of urea to ammonia and carbon dioxide. Ammonia, a
strongly alkaline agent, is a major cause of damage to host tis-
sues. It has been shown that ammonia derivatives, such as am-
monium hydroxide and monochloramine, are directly toxic to
mammalian cells (Burne and Chen 2000). On the other hand, ac-
cumulation of ammonium increases the pH in surrounding tis-
sues, thereby affecting the enzyme activities of the body system
and triggering stone formation in the bladder and kidney (Grif-
fith,Musher and Itin 1976; Burne andChen 2000). Similarly, it has
been demonstrated using animalmodels that urease-deficient P.
mirabilis strains are less virulent and have lower 50% lethal dose
(LD50) in comparison to parent strains (Jones et al. 1990). These
findings are further supported by the fact that treating the an-
imals with acetohydroxamic acid, a potent urease inhibitor, re-
duces the severity of P. mirabilis infection (Musher et al. 1975).
Hemolysin, another host damaging virulence factor of P.
mirabilis, has cytotoxic effects on urinary tract epithelial cells
(Mobley et al. 1991). It has been shown that hemolytic activity
correlates with the cell invasiveness of P. mirabilis strains in vitro
(Rozalski, Dlugonska and Kotelko 1986). This was further con-
firmed using a mouse model in which it was shown that the
hemolysin-negative strains had higher LD50 than hemolysin-
positive strains (Swihart and Welch 1990).
Biofilms, in particular crystalline biofilms, play a significant
role in P. mirabilis UTIs. Biofilms protect organisms from the host
immune systemand antimicrobials (Jacobsen and Shirtliff 2011).
Crystalline biofilms make P. mirabilis UTIs more complicated.
The crystallization of biofilms using magnesium phosphate and
calcium phosphate leads to biofilm encrustation and blockage
of indwelling catheters in patients with UTI (Mobley and War-
ren 1987).
According to the data presented above, urease, hemolysin
and biofilm of P. mirabilis can be excellent therapeutic targets
for treatment of P. mirabilis UTIs. This study aimed mainly to
investigate the in vitro efficacy of allicin in neutralizing urease
and hemolysin and to evaluate the effects of sub-inhibitory con-
centrations of allicin on biofilm formation in P. mirabilis. The an-
timicrobial activity of allicin against P. mirabilis strains was fur-
ther evaluated. Allicin as the active principle of garlic extract
possesses a number of pharmacological effects including an-
timicrobial activities (Harris et al. 2001). It has been shown that
allicin could interfere with bacterial virulence factors in sub-
minimum inhibitory concentrations (sub-MIC; Arzanlou and
Bohlooli 2010a; Arzanlou et al. 2011; Leng et al. 2011).
MATERIALS AND METHODS
Bacterial strains, chemicals and media
A total of 20 clinical strains and one standard strain of P. mirabilis
(ATCC 12453) were used in this study. Clinical strains were iso-
lated from patients with UTIs admitted to a major university-
affiliated teaching hospital (Imam Hospital, Ardabil University
of Medical Sciences) and further confirmed using standard bio-
chemical tests. Bacteria were cultured on trypticase soy agar
(TSA) slants for daily use and stored in a trypticase soy broth
medium along with 15% glycerol, at –80oC for subsequent uses.
All chemicals and media were purchased from Merck (Darm-
stadt, Germany), except where noted.
Allicin preparation and quantification
Allicin (purity ≥95%) was purified from garlic extract using the
semi-preparative HPLC method and quantified by analytical
HPLC as described in detail by authors elsewhere (Arzanlou and
Bohlooli 2010b; Arzanlou, Bohlooli and Ranjbar-Omid 2015).
Antimicrobial susceptibility assay
The antimicrobial activity assay of allicin against P. mirabiliswas
performed using a microdilution method according to proce-
dures recommended by the Clinical Laboratory Standards Insti-
tute (CLSI 2011). Briefly, 2-fold serial dilutions of allicin were pre-
pared in sterile Mueller Hinton Broth (MHB) for a testing concen-
tration range of 2–1024 μg mL−1. Then 100 μL from each dilution
was transferred into thewell of amicrotiter plate and inoculated
with 5 μL of standardized (1.5 × 107 CFU mL−1) cell suspension.
Plates were incubated at 37oC overnight, and the lowest concen-
tration of allicin that prevented visible growth was recorded as
the MIC. Minimum bactericidal concentration (MBC) was deter-
mined by sub-culturing 10 μL of broth fromwells with no visible
growth on TSA plates. The lowest concentration of allicin that
killed 99.9% of the original inoculum was considered as MBC.
Urease production and activity assay
A total of 50 μL of overnight culture of P. mirabilis ATCC 12453 in
MHB were transferred into 10 mL sterile MHB and additionally
incubated 18 h at 37oC with constant shaking. The cells were
pelleted by centrifugation at 1258 g for 15 min (4oC). The pellet
was washed three times with 10 mM K2HPO4 solution and re-
suspended in 2 mL of the same solution. Thereafter, to release
the urease, bacteria were sonicated for 90 s with 0.5 cycles at
100% amplitude using an ultrasonicator (UP200H, Hielscher Ul-
trasonics, Teltow, Germany) in an ice container. The resulting
bacterial lysate was used for urease activity assay. Urease activ-
ity assay was performed in a microtiter plate using the phenol
red colorimetric method in a mixture containing 10 mM K2HPO4
solution (pH 6.2), 0.002% phenol red and 500 mM urea (assay
reagent). The increase in absorbance at 570 nmwas recorded us-
ing a microplate reader (BioTek, USA) (Goldie et al. 1989; Tanaka,
Kawase and Tani 2003). Activity was calculated using a standard
curve relating to NH3 solutions of known concentration (Norris
and Brocklehurst 1976) and expressed as mmol NH3 min–1 mg–1
protein (Bauerfeind et al. 1997). In all experiments, the freshly
prepared bacterial lysate was used. To obtain solutions with the
same urease activity, the lysate was diluted to a defined specific
activity (5.66mmol NH3min–1 mg–1 protein) with 10mMK2HPO4
and then the same volume used in different experiments.
Inhibition of urease activity
To evaluate the inhibitory effects of allicin on urease, 15 μL
of bacterial lysates (approximately 1.7 mg protein) were pre-
incubated with various concentrations of allicin (1, 3, 5 and
7 μg), for 30 min at 37oC, and then the urease activity was mea-
sured as described above. The positive control for the assay was
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prepared in the same manner, but without the allicin. The ab-
sorbance values of each reaction were plotted against the time,
and the residual activity was calculated by dividing the slope of
the regression line obtained for each reaction by the slope of the
positive control. Similar experiments were done to evaluate the
inhibitory effects of iodoacetic acid (IAA) as a known urease in-
hibitor.
In parallel, to ensure that the color change was not due to al-
licin or urea, negative controls consisting of allicin without bac-
terial lysate or controls free of urea (with and without allicin)
were included.
Inhibition of urease inside the bacteria
The bacterial cell suspension with an optical density of 0.7 at a
wave length of 620 nm in 10 mM K2HPO4 solution (pH 6.2) was
incubated with 10, 25, 50 μg concentrations of allicin for 1 h at
room temperature. Thereafter, the bacteria were harvested by
centrifugation at 1258 g for 10 min and washed three times with
the same buffer to remove probable remaining allicin. Then, the
bacteria were resuspended in 10 mM K2HPO4 solution (pH 6.2)
and lysed with an ultrasonicator, and the urease activity was
assayed as described above.
Effects of a reducing agent on urease re-activation
An experiment was conducted to elucidate whether the reduc-
ing agent dithiothreitol (DTT) could restore urease activity af-
ter incubation with allicin. A total of 15 μL of bacterial lysates
(approximately 1.7 mg protein) was pre-incubated with differ-
ent inhibitory agents for 30 min at 37oC, and then the mixture
was further incubated in the presence of 4 μL DTT (5 mM fi-
nal concentration) for 30 min at room temperature. The activ-
ity of urease was measured as described above, and residual
activity was expressed as relative activity. In order to elucidate
the molecular mechanism of urease inhibition, the same exper-
iments were conducted on urease inhibited by IAA. Minimum
concentrations of agents which fully inhibit urease were used in
all experiments.
Hemolysin production and hemolytic activity assay
Culture and disruption of P. mirabilis ATCC 12453 were per-
formed in the same manner as urease production, except that
the culture was carried out without shaking and the lysate
was prepared in normal saline. The bacterial lysate was used
for hemolytic activity assay which was carried out using hu-
man red blood cells (RBCs) according to the method previously
described by authors (Arzanlou and Bohlooli 2010a). Briefly,
hemolytic activity was determined with serial dilutions of bac-
terial lysate in normal saline. Washed human type O RBCs were
added to the tubes to yield a final concentration of 2%. All tubes
were incubated at 37oC for 30 min. The remaining intact ery-
throcytes were removed by gentle centrifugation at 805 g for
2 min. The absorbance of released hemoglobin was determined
at 541 nm using a spectrophotometer. The amount of hemolysin
that produced 50% hemolysis was defined as 1 hemolytic unit
(HU). Controls containing 2% erythrocytes and de-ionized water
which were considered 100% hemolysis were used to determine
the percentage of hemolysis. All experiments were conducted in
triplicate.
Assay of hemolytic activity inhibition
Inhibition studies of hemolytic activity in the presence of al-
licin were carried out according to the method previously de-
scribed by authors (Arzanlou and Bohlooli 2010a). Bacterial
lysates (200 μL;∼1 HU) were pre-incubated with various concen-
trations (5, 10, 15, 20 μg) of allicin for 15 min at ambient temper-
ature. Washed RBCs were added to yield a final concentration of
2%. All tubes were incubated at 37oC for 30 min. To remove the
intact RBCs, tubeswere centrifuged gently at 805 g for 2min. The
absorbance of the released hemoglobin was determined at 541
nm. The positive control for the assay was prepared in the same
manner, but without allicin. Activity without the inhibitor was
considered to be 100%, and the residual activity at each concen-
tration of allicin was determined relative to this value. In par-
allel, to ensure that the lysis was not due to the test material, a
negative control consisting of allicinwithout bacterial lysatewas
included.
Growth curve
A suspension of P. mirabilis ATCC 12453 and two representative
clinical strains (with strong biofilm-forming abilities) with tur-
bidities equal to McFarland turbidity standard No. 0.5 were pre-
pared in normal saline. A total of 100 μL of the suspensions was
transferred into 10mL sterileMHB (1.5× 107 CFUmL−1) in 100mL
Erlenmeyer flasks containing 2, 4, 8, 16, 32, 64 and 128 μg mL−1
allicin. In parallel, a control without allicin was included. The
flasks were incubated at 37 ◦C with constant shaking under aer-
obic conditions. The growth of cells was measured by reading
the optical density (620 nm) of 100 μL samples at 2 h intervals,
up to 18 h. Optical density values from triplicate experiments
were averaged and plotted against time points.
Screening of strains for biofilm formation
To select the strains with strong biofilm-forming ability, all
strains (n = 21) were tested for their ability to form biofilm us-
ing polystyrene flat-bottomed microtiter plates (Orange Scien-
tific, Belgium) as described by O’Toole et al. 1999 with some
modifications. Briefly, 200 μL of sterile MHB was dispensed into
wells of a microtiter plate. The wells were inoculated with
10 μL of standardized (1.5 × 107 CFU mL−1) cell suspension. The
plates were incubated for 18 h at 37oC. Thereafter, the biofilm-
coated wells of microtiter plates were washed three times with
300 μL of sterile PBS (pH 7.4) to remove non-adherent cells, dried
in an inverted position in room temperature. Afterwards, each
of the washed wells was stained with 200 μL of 0.2% safranin
aqueous solution for 2 min and then washed three times with
300 μL of sterile distilled water to remove excess dye. The bacte-
ria were decolorized with 200 μL of 95% ethanol for 15 min, then
150 μL of the resolubilized dyes were transferred to a new well,
and the amount of the safranin stainwasmeasuredwith themi-
crotiter plate reader at a 492 nm wavelength. To minimize back-
ground interface, controls including bacteria-free medium were
included in each experiment, and the absorbance values for the
controls were subtracted from the values for the test wells and
defined as biofilm forming ability. All strains were tested in qua-
druplicate in three independent experiments.
Biofilm-forming ability was defined as strong (OD ≥ 0.3),
moderate (0.2 ≤ OD < 0.3), weak (0.2 > OD ≥ 0.1) and negative
(OD < 0.1) (Wasfi et al. 2012).
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Effects on biofilm formation
In this study, P. mirabilisATCC 12453 and two clinical strains with
strong biofilm-forming abilities were included. The effect of sub-
MIC concentrations of allicin on biofilm formation was evalu-
ated according to the method described above, except that bac-
teria were cultured in the presence of defined concentrations (2,
4, 8, 16 and 32 μg mL−1) of allicin. Biofilm formation without al-
licin was considered to be 100%, and the percentage of biofilm
inhibition at each concentration of allicin was determined rela-
tive to this value.
Effects on established biofilm
The effect of allicin on established biofilms was investigated
as described by others with some modifications (Nostro et al.
2007). Bacteria were grown as biofilm using the same method
described above. Planktonic phase cells were removed and the
wells were washed three times with PBS. Then, the wells were
filled with 200 μL of 2-fold multiples of allicin in MHB, ranging
from MIC to 5-fold multiples of MIC. The plates were incubated
24 h at 37oC. The biofilm inhibitory concentration (BIC) was de-
fined as the lowest concentration where no visible growth was
observed. Samples of biofilms from the bottom of these wells
were scarified by a metal loop, spread over the surface of TSA
plates, and incubated for 72 h at 37oC. The biofilm eradication
concentration (BEC)was taken as theminimumconcentration at
which viable cells could no longer be recovered from the biofilm
directly.
Statistical analysis
All experiments were repeated at least three times and obtained
data was presented as mean ± SD. Statistical analysis was per-
formed using Student’s t-test, and P < 0.05 was considered sig-
nificant. The half-maximum inhibitory concentration (IC50) val-
ues for the inhibition study of urease activity were calculated by
fitting data to the Hill equation using SigmaPlot (version 11.0)
software (Systat Software).
RESULTS
Purification of allicin
A typical representative chromatogram of purified allicin is
shown in Fig. 1. As shown in the chromatogram, purified allicin
Figure 1. Representative chromatogram of purified (A) and standard (B) allicin using analytical HPLC.
D
ow
nloaded from
 https://academ
ic.oup.com
/fem
sle/article-abstract/362/9/fnv049/548593 by Tehran U
niversity of M
edical Science user on 13 January 2020
Ranjbar-Omid et al. 5
Table 1. Susceptibility of P. mirabilis clinical strains to purified allicin.
MIC (μg mL−1) Strains n (%) MBC (μg mL−1) Strains n (%)
64 3 (14.3) 64 –
128 18 (85.7) 128 1 (4.7)
256 – 256 9 (42.8)
512 – 512 11 (52.4)
Total 21 (100) Total 21 (100)
Figure 2. Inhibition of urease activity in bacterial cell lysate using allicin. Bacte-
rial cell lysate was incubated for 30 min with defined concentrations of allicin
and the urease activity was assayed. Results were obtained from three indepen-
dent triplicate experiments. Relative activity was calculated in comparison to
the allicin-free control and expressed as mean ± SD. ∗statistically significant
(P < 0.05) compared with the allicin-free control. ∗∗statistically significant (P <
0.001) compared with the allicin-free control.
yielded a single peak with a retention time of 6 min, inconsis-
tent with standard allicin, and constituted ≥ 95% of the total de-
tectable peak areas.
Antimicrobial susceptibility assay
The results showed that allicin was active against P. mirabilis
strains. The tested clinical isolates revealed the MICs of ei-
ther 64 or 128 μg mL−1and MBCs of either 128 or 512 μg mL−1
(Table 1). The MIC 90 and MBC 90 for tested strains were 128
and 512 μg mL−1, respectively. The MIC and MBC for the control
strain tested (P. mirabilis ATCC 12453) were 64 and 128 μg mL−1,
respectively.
Inhibition of urease activity in bacterial lysate
The results showed that allicin decreased urease relative ac-
tivity in a concentration-dependent manner. Fig. 2 represents
the decrease of urease activity after 30 min pre-incubation with
increasing concentrations of allicin. IC50 was achieved with
4.15 μg of allicin and 7 μg completely inhibited urease compared
with the allicin-free control. Urea-free controls showed no ac-
tivity with or without allicin (data are not shown). Similar to al-
licin, IAA inhibited urease activity in a concentration-dependent
manner, and maximum inhibition was achieved at 8 μg (Fig. 3).
Inhibition of urease activity inside the bacteria
The results showed that allicin easily diffused into bacteria and
inhibited urease relative activity in a concentration-dependent
manner. Fig. 4 shows that urease activity decreased as allicin
concentrations increased after 30 min pre-incubation of intact
Figure 3. Inhibition of urease activity in bacterial cell lysate using IAA. Bacte-
rial cell lysate was incubated for 30 min with defined concentrations of allicin
and the urease activity was assayed. Results were obtained from three indepen-
dent triplicate experiments. Relative activity was calculated in comparison to
the IAA-free control and expressed as mean ± SD. ∗statistically significant (P <
0.05) compared with the IAA-free control. ∗∗statistically significant (P < 0.001)
compared with the IAA-free control.
Figure 4. Inhibition of urease enzyme inside intact bacterial cell using allicin. The
bacterial cells were disrupted after exposure to defined concentrations of allicin
(30 min at room temperature) and the urease activity was assayed. Residual ac-
tivity was calculated in comparison with the allicin-free control and expressed
as mean ± SD. Results were obtained from three independent triplicate experi-
ments. ∗statistically significant (P < 0.05) compared with the allicin-free control.
∗∗statistically significant (P < 0.001) compared with the allicin-free control.
cells with allicin. The IC50 was 21.01 μg, while 50 μg completely
inhibited urease.
Effects of a reducing agent on urease inhibition
by allicin
Results indicated that the incubation of allicin-treated urease
(7 μg) with 5 mM DTT restored its enzymatic activity (P > 0.001).
DTT did not restore the inhibitory effect of IAA (Fig. 5).
Inhibition of hemolytic activity
As demonstrated in Fig. 6, allicin did inhibit the hemolytic activ-
ity of P. mirabilis hemolysin (P > 0.05).
Screening of strains for biofilm formation
Tested strains showed variable results in the aspect of biofilm
formation. Most clinical strains as well as the P. mirabilis strain
ATCC 12453 were put into the strong biofilm-former category
(75, 20 and 5%were strong, moderate and weak biofilm-formers,
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Figure 5. Effect of DTT on restoring urease activity after incubation with allicin
and IAA. Bacterial cell lysate was incubated for 30 min with 7 and 8 μg concen-
trations of allicin and IAA, respectively. The reactions were further incubated
with DTT (5mM) for 30min. Residual activity was calculated in comparisonwith
DTT-free controls and expressed asmean± SD. Resultswere obtained from three
independent triplicate experiments. DTT did not restore the inhibitory effect of
IAA (P > 0.05). ∗statistically significant (P < 0.001) compared with the DTT-free
control.
Figure 6. Inhibitory effects of allicin on the hemolytic activity of P. mirabilis. Bac-
terial lysate was pre-incubated for 30 min with various concentrations of pure
allicin (5, 10, 15, 20 μg). Hemolytic activity was measured and residual activ-
ity was calculated in comparison with the allicin-free control. Results were ob-
tained from three independent triplicate experiments and expressed as mean
± SD. Allicin did not inhibit the hemolysin (P > 0.05) compared with the allicin-
free control.
respectively). Two isolates from the strongest biofilm-forming P.
mirabilis strains were selected for biofilm inhibition studies.
Effects of sub-inhibitory concentrations of allicin
on P. mirabilis growth
Fig. 7 shows the growth curve of P. mirabilis strain ATCC 12453 in
the presence of increasing concentrations of allicin. As shown
in the figure, sub-MIC concentrations of allicin at 2–32 μg mL−1
had no significant influence on P. mirabilis growth (P > 0.05) at
18 h after the inoculation of bacteria into the culture medium.
Allicin at 32 μg mL−1 delayed bacteria growth in the first hours
after the inoculation of bacteria into the culture medium; but
increasing the incubation time up to 18 h produced no signifi-
cant difference in growth compared with the allicin-free control
(P > 0.05). At concentrations equal to or above the MIC value,
allicin completely inhibited growth. The growth of two clinical
strains tested showed similar responses to allicin (data are not
shown).
Effects of allicin on biofilm development
Allicin reduced biofilm formation in a concentration-dependent
manner in P. mirabilis (Fig. 8). Allicin at 16 and 32μgmL−1 showed
the maximum reduction in biofilm development by 28.9% ± 0.2
and 33.8% ± 1.0 in P. mirabilis strain ATCC 12453, 27.5% ± 0.3 and
35.1% ± 1.0 in clinical isolate 1, and 16.4% ± 0.1 and 25.7% ± 0.1
in clinical isolate 2.
Effects of allicin on established biofilm
The BIC and BEC of allicin for tested P. mirabilis strain ATCC 12453
were 2-fold (256 μg mL−1) and 4-fold (512 μg mL−1) greater than
its MBC, respectively. The MIC and MBC values for this strain
were 64 and 128 μg mL−1 in MHB, respectively.
DISCUSSION
The pathogenesis of P. mirabilis is multifactorial, and plenty of
virulence factors work together to cause diseases. Inhibiting vir-
ulence factors could attenuate bacterium and enable the host
immune system to combat disease. Wide varieties of natural
products have been studied to inhibit P. mirabilis virulence fac-
tors (Wang et al. 2006; Carpinella et al. 2011; Cock and van Vuuren
2014; Packiavathy et al. 2014). The current study reports the in-
hibitory effects of allicin on the urease, hemolysin and biofilm
of P. mirabilis as well as its antimicrobial activity against the bac-
terium. Allicin is a natural product derived from garlic (Allium
sativum). It was found to inhibit the growth of a wide range of
bacteria; it also showed antiparasitic, antifungal and antiviral
activity in vitro (Harris et al. 2001). Allicin is commercially avail-
able, but its instability and high price limit the amount that can
be used. Several previous studies on the antimicrobial activity
of allicin have been carried out essentially with garlic extract
rather than purified allicin. In this study, purified allicin was
used in all experiments. The results showed that allicin inhibits
the growth of themajority of P. mirabilis strains at concentrations
lower than the MIC values previously reported to other Gram-
negative bacilli, Pseudomonas aeruginosa, and oral anaerobic bac-
teria (Cai et al. 2007; Bachrach et al. 2011). Urease is suggested
as an important target in the development of drugs for treating
infection caused by urease positive bacteria (Follmer 2010). The
activity of P. mirabilis ureases can be inhibited by substrate struc-
tural analogs of urea (such as hydroxyurea, thiourea, methy-
lurea, and hydroxamic acid derivatives and phosphotriamides)
and proton-pump inhibitors (such as rabeprazole, omeprazole
and lansoprazole) (Follmer 2010). Proton-pump inhibitors indi-
rectly inhibit urease. In a low pH environment, they are con-
verted to sulfonamides which, in turn, inhibit urease via cys-
teine modification at the active site of the enzyme (Nagata et al.
1993; Tsuchiya et al. 1995). Unique features of bacterial urease
are its association with nickel and its large number of cysteine
residues (Rando et al. 1990). Cysteine-319 is key residue at the
active site of P. mirabilis urease (Sriwanthana and Mobley 1993).
Results of the current study showed that allicin efficiently in-
hibited P. mirabilis urease, likely via a mechanism involving the
formation of a disulfide bond with reactive cysteine residue at
the urease active site. This mechanism was further confirmed
by the restoration of activity of the enzyme in the presence
of a reducing agent, DTT. This is consistent with the proposed
mode of action for allicin to form a disulfide bond with cysteine
residue at the active site of enzymes, and consequently to inhibit
the catalytic activity of urease (Rabinkov et al. 1998). Previous
studies on jack bean urease (Juszkiewicz et al. 2003), microbial
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Figure 7. Growth curves of P. mirabilis strain ATCC 12453 cultured in MHB in presence of allicin. Allicin concentrations (μg mL−1): (filled square) 2, (filled diamond) 4,
(filled triangle) 8, (open triangle) 16, (open circle) 32, (star) 64, (filled circle) 128, (open square) Control without allicin. The OD 620 nm was not statistically significant
(P > 0.05) compared with the allicin-free control at 18 h in sub-MIC concentrations.
Figure 8. Inhibition of biofilm formation by sub-MIC concentrations of allicin. Bacteria were cultured in the presence of sub-MIC concentrations (μg mL−1) of allicin
[(black filled square) 2, (open square) 4, (gray filled square) 8, (square filled with diagonal lines) 16, (square filled with horizontal lines) 32] for 18 h and biofilm develop-
ment was assayed. Inhibition percentage was calculated in comparison with the allicin-free control and expressed as mean ± SD. Results were obtained from three
independent triplicate experiments. Statistically allicin (all concentrations) did inhibit biofilm formation compared with the allicin-free control (P < 0.001).
SH-containing enzymes (Wills 1956;Wallock-Richards et al. 2014)
and toxins (Arzanlou and Bohlooli 2010a; Arzanlou et al. 2011)
suggested the same mode of action for allicin. This mechanism
of actionwas further confirmed by comparisonwith IAA as an ir-
reversible inhibitor of cysteine containing enzymes. IAA inhibits
urease activity with themechanism of inhibition occurring from
the alkylation of the catalytic cysteine residue (Upadhyay 2012).
As expected, DTT did not restore its activity.
Inhibition of urease inside the intact bacteria revealed that
allicin efficiently diffuses into cytoplasm and inhibits urease.
Previous studies indicated that allicin could easily pass through
biological membranes (Miron et al. 2000). Passing through bac-
terial envelopes could be an excellent advantage of allicin
over other urease inhibitors. A few urease inhibitors such as
hydroxamic acid derivatives are known to penetrate the Heli-
cobacter pylori cells and inhibit urease activity inside the bacteria
(Nakamura et al. 1998; Follmer 2010).
Significantly higher concentrations of allicin were required
to completely inhibit urease activity inside intact cells com-
pared to pre-lysed P. mirabilis. These results are consistent
with previous reports showing that complete inhibition of En-
tamoeba histolytica cysteine proteases and Streptococcus pneumo-
nia pneumolysin in intact organisms occurs at higher concen-
trations compared with pre-lysed organisms (Ankri et al. 1997;
Arzanlou et al. 2011). Complete inhibition for both was achieved
at concentrations lower than MIC values as determined for P.
mirabilis in this study. The low inhibitory concentration of al-
licin toward P. mirabilis urease is likely due to some allicin
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features such as a high affinity toward -SH groups (Rabinkov
et al. 1998; Arzanlou and Bohlooli 2010a; Arzanlou et al. 2011),
low molecular weight and simple structure which make it eas-
ier to enter the active sites of sulfhydryl enzymes/toxins. How-
ever, several other factors including molecular structure (which
may play a role in the inhibitor accessing active sites) and the
concentration of enzymes influencing the inhibitory effect of
allicin.
Allicin did not affect the hemolytic activity of P. mirabilis
hemolysin in spite of previous studies by the authors on pneu-
molysin O (PLY) and streptolysin O (SLO) (Arzanlou and Bohlooli
2010a; Arzanlou et al. 2011). It was indicated that allicin inhibits
PLY and SLO by binding to the cysteinyl residue in their bind-
ing sites (Arzanlou and Bohlooli 2010a; Arzanlou et al. 2011).
Unlike PLY and SLO, the P. mirabilis hemolysin active site does
not contain free cysteine residues in its structure, so the inef-
fectiveness of allicin on P. mirabilis hemolysin activity could be
explained by the lack of free cysteine residues in its structure
(Weaver et al. 2009). Beside the chemical inactivation of bacte-
rial virulence factors by allicin, other studies showed that sub-
MIC concentrations of allicin could reduce the production of
Staphylococcus aureus hemolysin (α toxin) at the genomic level
(Leng et al. 2011).
The other experimental approach of the current study was to
examine the effects of allicin on biofilm formation by P. mirabilis
and its effect on established biofilms. Previous studies have
shown that allicin could reduce biofilm formation in S. epider-
midis, P. aeruginosa and Candida albicans at sub-MIC concentra-
tions (Perez-Giraldo et al. 2003; Khodavandi et al. 2011; Lihua
et al. 2013). The current study showed that allicin also can inhibit
biofilm development in P. mirabilis at sub-MIC concentrations. In
addition, allicin was found to be effective in inhibiting estab-
lished biofilms at higher concentrations. These results are con-
sistent with previous reports that state that bacteria are more
resistant in biofilm than in planktonic growth (Patel 2005; Jacob-
sen and Shirtliff 2011). Biofilms in particular crystalline biofilms
play a significant role in P. mirabilis UTIs (Jacobsen and Shirtliff
2011). Alkaline pH plays an essential role in the development
of crystalline biofilms, so impeding the rise of urinary pH and
subsequent crystallization could be a critical step in prevent-
ing biofilm formation. Urease inhibitors, such as flurofamide,
have shown to reduce the development of crystalline biofilms,
since they reduce pH and consequently reduce the deposition
of calcium and magnesium salts on biofilm (Morris and Stickler
1998). As discussed earlier, allicin as a potent P. mirabilis urease
inhibitor may prevent the development of crystalline biofilms in
P. mirabilis. Therefore, further studies may be worthy of evalua-
tion.
CONCLUSION
The results of this study revealed that allicin inhibited the
growth of P. mirabilis. This compound also reduced the biofilm
development and neutralized the urease enzyme of P. mirabilis.
The main drawback of clinical application of allicin is its insta-
bility in biological fluids (Freeman and Kodera 1995). It has been
previously shown that allicin is broken down in the body (Rosen
et al. 2001), and this limits its clinical application. Some stud-
ies examined the formation of allicin on target cells inside the
body using pro-drug enzyme systems (Arditti et al. 2005; Appel
et al. 2011). This systemmay be applied to control P. mirabilisUTIs
using allicin. However, to achieve this goal further studies are
needed.
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